At a glance
- Originator Kyowa Hakko
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 12 Feb 1998 No-Development-Reported for Atherosclerosis in Japan (Unknown route)
- 21 Mar 1995 Preclinical development for Atherosclerosis in Japan (Unknown route)